Alzheon Initiates Phase 1 Trial of ALZ-507, Next-Generation Oral Alzheimer's Drug with APOE4 Corrector Mechanism
核心洞察
Alzheon has dosed the first subject in a Phase 1 clinical trial of ALZ-507, a novel oral drug candidate designed to inhibit neurotoxic soluble amyloid oligomers (搜索) in Alzheimer's disease (搜索).
ALZ-507 features a dual mechanism of action, targeting upstream amyloid aggregation while also functioning as an APOE4 (搜索) corrector to enhance its anti-oligomer properties.
The investigational therapy is designed for once-daily dosing with improved gastrointestinal tolerability compared to existing treatments.
Alzheon, Inc. has announced the dosing of the first cohort of human volunteer subjects in a Phase 1 clinical trial of ALZ-507, a novel investigational oral drug candidate for Alzheimer's disease (搜索) treatment. The milestone represents a significant advancement in the company's precision medicine platform targeting neurotoxic soluble amyloid oligomers (搜索).
Novel Dual Mechanism of Action
ALZ-507 is an orally administered small molecule developed to target upstream amyloid aggregation and inhibit the formation of neurotoxic soluble amyloid oligomers (搜索), which are recognized as a key trigger and driver of Alzheimer's disease (搜索) pathology. The drug candidate features a distinctive dual approach, combining its primary anti-oligomer effects with an APOE4 (搜索) corrector mechanism of action.
"This well-differentiated next-generation Alzheimer's drug candidate also functions as an APOE4 (搜索) corrector, strengthening its anti-oligomer properties," said Martin Tolar, MD, PhD, Founder, President, and CEO of Alzheon. "ALZ-507 is a major step forward for Alzheon's precision medicine platform aimed at the prevention of formation of neurotoxic soluble amyloid oligomers (搜索)."
Enhanced Pharmaceutical Profile
Designed as a next-generation oral treatment for Alzheimer's disease (搜索), ALZ-507 may offer the advantages of once-daily dosing and improved gastrointestinal tolerability. Preclinical studies have demonstrated evidence of a positive safety and pharmacokinetic profile, as well as an enhanced efficacy profile, according to the company.
"Building on our experience with upstream inhibition of amyloid aggregation, ALZ-507 further expands our portfolio of oral treatments designed to target the main causes of neurodegeneration," stated John Hey, PhD, Chief Scientific Officer at Alzheon.
Phase 1 Trial Design and Future Applications
The Phase 1 clinical trial will assess the safety, tolerability, and pharmacokinetics of both single and multiple ascending doses of ALZ-507 using an oral capsule formulation in healthy volunteer participants. Findings from this investigation are anticipated to guide dose selection and inform formulation strategy for subsequent Phase 2 studies.
The planned Phase 2 studies will involve patients diagnosed with multiple conditions including Alzheimer's disease (搜索), Down syndrome-associated AD (搜索), and cerebral amyloid angiopathy (搜索) (CAA), demonstrating the broad therapeutic potential of the compound.
Expanding Pipeline Beyond ALZ-801
ALZ-507 represents an evolution from Alzheon's lead candidate, valiltramiprosate/ALZ-801, which is currently in Phase 3 development. ALZ-801 received Fast Track designation from the U.S. Food and Drug Administration (搜索) in 2017 for Alzheimer's disease (搜索) treatment and has demonstrated strong clinical efficacy at the mild cognitive impairment (搜索) stage with a favorable safety profile, including no observed increase in the risk of brain vasogenic edema.
The APOLLOE4 Phase 3 trial evaluated 265 mg twice daily oral doses of valiltramiprosate in Early AD subjects with two copies of the apolipoprotein ε4 allele (搜索) (APOE4 (搜索)/4 homozygotes), who constitute approximately 15% of Alzheimer's patients. The trial was supported by a grant from the National Institute on Aging.
Precision Medicine Approach
Alzheon's development strategy incorporates individual genetic and biomarker profiles, with particular focus on APOE4 (搜索) carriers who represent 65-70% of Alzheimer's patients. The company's precision medicine approach aims to advance therapies with meaningful benefits for patients by targeting the underlying pathology of neurodegeneration.
"With Alzheimer's disease (搜索) still representing a critical global unmet medical need, we are committed to work toward bringing to patients novel, safe, and accessible therapies that have the potential to slow disease progression," Tolar emphasized.